GSK

Ahead Together

Our pathway to net zero impact on climate

March 2026

We're committed to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

This document gives more detail on the pathway we have set to a net zero impact on climate, although there are many interdependencies with our nature goals.

Our climate targets

We have set a clear pathway to a net zero impact on climate. By 2030, we aim to reduce carbon emissions by 80% with the remainder covered through investment in high-quality nature-based solutions, and by 2045, we aim to be at the Science Based Target Initiative Net Zero Standard, with carbon emissions reduced by at least 90% and the remainder tackled through high-quality carbon credits.

2025

- 100% imported renewable electricity by 2025

Achieved

2030

- 80% absolute reduction in greenhouse gas emissions from a 2020 baseline, across all scopes and investment in nature-based solutions for the remaining 20% of our footprint by 2030
- 100% renewably imported and generated electricity by 2030

2045

- Net zero greenhouse gas emissions across our full value chain by 2045: 90% absolute reduction in emissions from a 2020 baseline, across all scopes and all residual emissions neutralised

- **Our net zero targets cover the full value chain of emissions reductions, from a baseline of 2020.**
- **Our net zero targets have been approved by the Science Based Target Initiative's Corporate Net-Zero Standard, the world's only framework for corporate net-zero target setting in line with climate science.[1]**
- **We disclose progress against these targets annually in our Annual Report and Responsible Business Report.**

1 You can find our approved targets on the SBTi website here

Our value chain carbon footprint

We have mapped our carbon footprint across our value chain to ensure we have a clear understanding of where to focus our efforts, which informs our pathway to net zero.

Supply chain

Scope 3 emissions from the goods and services that GSK buys from other companies and other upstream emissions.



3.4m tonnes CO_2e per annum

Purchased goods	1.83m tonnes CO_2e per annum
Purchased services	1.04m tonnes CO_2e per annum
Capital investments	0.26m tonnes CO_2e per annum
Business travel	0.13m tonnes CO_2e per annum
Upstream energy	0.08m tonnes CO_2e per annum
Commuting	0.06m tonnes CO_2e per annum

GSK's operations

Scope 1 and 2 emissions from running our labs, factories and commercial offices.*



0.6m tonnes CO_2e per annum

Energy	0.33m tonnes CO_2e per annum
HFA and manufacturing emissions	0.19m tonnes CO_2e per annum
Sales force	0.04m tonnes CO_2e per annum

* Scope 1 and 2 market-based emissions

Logistics

Scope 3 emissions from delivering medicines and vaccines across the globe.



0.3m tonnes CO_2e per annum

Upstream logistics	0.31m tonnes CO_2e per annum
Downstream logistics	0.03m tonnes CO_2e per annum

Patient use

Scope 3 emissions from patients using our products.



4.7m tonnes CO_2e per annum

Use of metered dose inhalers	4.64m tonnes CO_2e per annum
Use of other products	0.01m tonnes CO_2e per annum

Disposal

Scope 3 emissions from the disposal of our products by GSK patients.



0.1m tonnes CO_2e per annum

Products end of life treatment	0.05m tonnes CO_2e per annum
Operational waste	0.03m tonnes CO_2e per annum

9.03m
Total estimated GSK emissions
tonnes CO_2e per annum*

* based on data from 2024

Priority actions to reduce emissons

We are taking action to reduce emissions across our full value chain, prioritising the highest impact areas.

Purchased goods and services

Scope 3 emissions



3.4m tonnes CO_2e per annum

- Use product life cycle assessments to identify and execute the most impactful decarbonisation projects with our suppliers
- Work with 15 highest emitting suppliers to build, and performance manage 2030 decarbonisation plans
- Set joint minimum supplier sustainability targets through the Sustainable Markets Initiative (SMI) for climate and nature
- Power Purchase Agreements through Energize and SMI programmes to support renewable electricity transition for suppliers in Europe, North America, India, China, and Japan
- Offer capability building resources to suppliers through the Pharmaceutical Supply Chain Initiative, Activate programme, and SMI to support suppliers to reduce their carbon footprint

GSK's operations

Scopes 1 and 2 emissions



0.6m tonnes CO_2e per annum

Renewable electricity and heat

- Members of RE100
- Onsite production through wind turbines and solar panels, together with buying renewable electricity and through power purchase agreements
- Starting to generate heat through renewable electricity or biofuels

Electric vehicles

- Members of EV100
- Committed to transition our fleet to low-carbon vehicles by 2030
- Target to install charging infrastructure at 100 locations

Energy reductions

- Ongoing focus on energy efficiency programmes

Logistics

Scope 3 emissions



0.3m tonnes CO_2e per annum

- Maximising transition from air freight to sea freight
- Using AI to optimise route options
- Exploring solutions to reduce need for cold-chain storage for vaccines

Patient use

Scope 3 emissons



4.7m tonnes CO_2e per annum

- Predominantly from the propellant used in metered dose inhalers (MDIs) for asthma and chronic obstructive pulmonary disease
- Investing in a low-carbon programme, with pivotal Phase III data generated to support future regulatory submissions. Subject to regulatory review and approval, this next generation propellant is designed to reduce greenhouse gas emissions by 92%
- Beyond MDIs, product stewardship programme to embed eco-design principles for all new products

Disposal

Scope 3 emissions



0.1m tonnes CO_2e per annum

- Participating in industry takeback schemes for medical devices in Denmark, Singapore and Switzerland, and exploring opportunities for programmes in other countries

Our approach to carbon credits

Whilst we are focused on emissions reductions to meet our carbon targets, at the same time, we are investing in high quality nature protection and restoration projects that support our net-zero and nature positive goals, and deliver co-benefits to human health.

We plan to secure carbon credits for the 20% emissions we estimate to have as residual in 2030, and for a maximum of 10% residual emissions by 2045 (from a 2020 baseline). We aim to secure all of the credits for the 2030 target through nature investments by 2028 and we report our progress annually in the Responsible Business Report. These credits will be issued later in the decade and will be retired against our 2030 residual emissions and onwards, yearly.

For our 2030 target we are prioritising carbon removal credits, but we will also secure a proportion of carbon avoidance and reductions credits in recognition of their critical role in conserving existing carbon stocks and protecting nature. For our 2045 Net Zero target, we will aim to only secure carbon removal credits.

We plan to secure carbon credits for the 20% emissions we estimate to have as residual in 2030, and for a maximum of **10% residual emissions by 2045**.

Credit quality and integrity

We understand the scepticism around the quality of some of the existing carbon credits in the Voluntary Carbon Market (VCM). We aim to invest in high quality and high integrity projects:

- We partner with expert developers and NGOs to invest in early-stage projects for the long term and ensure the design is inclusive of nature and health co-benefits.
- We work with external experts to identify appropriate criteria for investments, covering carbon technical aspects (scientific verification, additionality, leakage, permanence, etc) and other impacts (avoidance of harm, benefit-sharing mechanism, IPLC and vulnerable communities' co-benefits, scientific innovation, etc).
- We work with multiple partners to run extensive due diligence on projects before investments.
- We continue to review evolving and emerging guidance documents, including those provided by the Voluntary Carbon Market Initiative and Science Based Targets Initiative, to ensure we are aligned with leading experts guiding the use of carbon credits.
- In partnership with Pollination, and with input from key nature and health experts from organisations such as the Circular Bioeconomy Alliance, the Nature Climate Solutions Alliance and the London School of Hygiene and Tropical Medicine, we have published an open-source toolkit to support companies, investors and developers to incorporate health considerations in the design of nature-based projects.
- We are open to co-investment opportunities if they increase the scale of the potential impact on the ground and reduce the risks intrinsic in nature projects.

Current projects in our portfolio

GSK is an investor in Climate Asset Management's Nature Based Carbon Fund, which aims to invest at a landscape scale in grassland, agriculture, forestry, wetlands and coastal carbon projects in developing economies, to provide long-lasting, verified, positive impact at scale for the climate, biodiversity and local communities.

We have invested in a peat and mangrove protection and restoration project in Indonesia. Rewetting, reforestation, monitoring, and fire prevention measures will enable emission reductions and long-term carbon storage, as well as biodiversity protection.

The project includes specific interventions such as training, supporting sustainable economic activities, and a Healthy Village Program, which involves initiatives such as providing capacity building to the community healthcare workers and health education for the local communities concerning sanitation, nutrition and newborn care.

We are part of the LEAF coalition (Lowering Emissions by Accelerating Forest finance), a private-public effort to protect tropical forests.

We recognise that this is a fast-moving space, and that methodologies and guidelines will likely evolve as we implement our plans.

We commit to remaining flexible and transparent about our progress and learning.

Our pathway to net zero

The graph below shows our projected carbon reduction pathway to 2030 and 2045 across the different parts of our carbon footprint, along with our planned carbon credits.



Ahead Together

More information

– Our position on Pharmaceuticals in the Environment

– Our position on Antimicrobial Resistance

– Our plan for contributing to a nature positive world

gsk.com